price month
erratum origin version note publish earlier today
incorrectli list ep correct number
updat model incorpor actual adjust
project account oper margin expans guidanc
manag consist deliv expect result
ahead consensu guidanc total revenu non-gaap
ep expect compani keep build improv fundament
keep cost check project continu oper margin expans
though measur pace compar actual
bp improv yoy project non-gaap oper margin
close upper end guidanc expand
anoth bp non-gaap ep vs
prior vs
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
alexion biotechnolog compani focus research
develop commerci therapeut rare diseas
alexion drug soliri use treat patient complement
mediat disord product includ strensiq
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
abl convert major soliri patient prior
launch biosimilar continu strength gmg launch
posit nmo data increas pipelin valu
unabl convert major soliri patient
prior launch biosimilar eu/row weak gmg
trend failur nmo decreas pipelin valu
 close
compani mention price
